evaluation of serum carnitine concentration in patients with urological malignancy and the effect of levocarnitine to them

evaluation of serum carnitine concentration in patients with urological malignancy and the effect of levocarnitine to them - the effect of levocarnitine to patients with urological malignancy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025757

Enrollment

Registered

2017-01-21

Start date

2017-11-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology

Interventions

carnitine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) urothelial carcinoma, prostate cancer, kidney carcinoma and testicular tumor disease (2) Patients scheduled for chemotherapy treatment

Exclusion criteria

Exclusion criteria: (1) A person who falls under the administration contraindication (2) Persons undergoing dialysis, those with advanced renal dysfunction (3) Those who did not finally obtain consent (4) Others that other medical doctor deems inappropriate

Design outcomes

Primary

Measure	Time frame
Measurement of carnitine concentration	—

Countries

Japan

Contacts

Public ContactRyoei Hara

Kawasaki Medical School Urology

ryoeih@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026